Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Catherine O'Brian

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Living Beings

Rats
Mice

Physiology

Genes & Molecular Sequences

Amino Acid Sequence

Concepts & Ideas

Phenomena

Phosphorylation

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
44
Ward, Nancy
14
Ioannides, Constantin
13
Gravitt, KR
13
Fan, Dominic
10
Chu, Feng
10
Stewart, Jubilee
9
Weinstein, Bernard
8
Fidler, Isaiah
6
Liskamp, Rob
5
Wharton, Taylor
5
Fisk, Bryan
4
Murray, James
4
Kudelka, Andrzej
3
Guillem, Jose
3
Bucana, Corazon

Sign-in to see all Coauthors

Publications

TOP 3
O'Brian Catherine A; Chu Feng; Bornmann William G; Maxwell David S
Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery?
Chu Feng; Koomen John M; Kobayashi Ryuji; O'Brian Catherine A
Identification of an inactivating cysteine switch in protein kinase Cepsilon, a rational target for the design of protein kinase Cepsilon-inhibitory cancer therapeutics.
Chu Feng; O'Brian Catherine A
PKC sulfhydryl targeting by disulfiram produces divergent isozymic regulatory responses that accord with the cancer preventive activity of the thiuram disulfide.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Catherine O'Brian (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2006: O'Brian Catherine A; Chu Feng; Bornmann William G; Maxwell David S
Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery?
Expert review of anticancer therapy 2006;6(2):175-86.
2005: Chu Feng; Koomen John M; Kobayashi Ryuji; O'Brian Catherine A
Identification of an inactivating cysteine switch in protein kinase Cepsilon, a rational target for the design of protein kinase Cepsilon-inhibitory cancer therapeutics.
Cancer research 2005;65(22):10478-85.
2005: Chu Feng; O'Brian Catherine A
PKC sulfhydryl targeting by disulfiram produces divergent isozymic regulatory responses that accord with the cancer preventive activity of the thiuram disulfide.
Antioxidants & redox signaling 2005;7(7-8):855-62.
2005: O'Brian Catherine A; Chu Feng
Post-translational disulfide modifications in cell signaling--role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission.
Free radical research 2005;39(5):471-80.
2005: Stewart Jubilee R; O'Brian Catherine A
Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells.
Molecular cancer therapeutics 2005;4(5):726-32.
2004: Stewart Jubilee R; O'Brian Catherine A
Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition.
Investigational new drugs 2004;22(2):107-17.
2004: Chu Feng; Chen Li Hua; O'Brian Catherine A
Cellular protein kinase C isozyme regulation by exogenously delivered physiological disulfides--implications of oxidative protein kinase C regulation to cancer prevention.
Carcinogenesis 2004;25(4):585-96.
2003: Stewart Jubilee R; Artime Marlene C; O'Brian Catherine A
Resveratrol: a candidate nutritional substance for prostate cancer prevention.
The Journal of nutrition 2003;133(7 Suppl):2440S-2443S.
2003: Chu Feng; Ward Nancy E; O'Brian Catherine A
PKC isozyme S-cysteinylation by cystine stimulates the pro-apoptotic isozyme PKC delta and inactivates the oncogenic isozyme PKC epsilon.
Carcinogenesis 2003;24(2):317-25.
2003: O'Brian Catherine A; Ward Nancy E; Chu Feng; Stewart Jubilee R
Irreversible inactivation of protein kinase C isozymes by thiol-reactive peptide substrate analogs.
Methods in molecular biology (Clifton, N.J.) 2003;233():441-9.
2002: Castilleja Agapito; Carter Darrick; Efferson Clay L; Ward Nancy E; Kawano Kouichiro; Fisk Bryan; Kudelka Andrzej P; Gershenson David M; Murray James L; O'Brian Catherine A; Ioannides Constantin G
Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(7):3545-54.
2002: Castilleja Agapito; Ward Nancy E; Epstein Richard B; Kudelka Andrzej P; Gershenson David M; Efferson Clay L; O'Brian Catherine A; Ioannides Constantin G
Treatment with HER-2 phosphorylation agonists enhance tumor ability to stimulate epitope specific CTL in vitro.
Oncology reports 2002;9(5):929-35.
2002: Ward Nancy E; Chu Feng; O'Brian Catherine A
Regulation of protein kinase C isozyme activity by S-glutathiolation.
Methods in enzymology 2002;353():89-100.
2001: Le X F; Marcelli M; McWatters A; Nan B; Mills G B; O'Brian C A; Bast R C
Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity.
Oncogene 2001;20(57):8258-69.
2001: Chu F; Ward N E; O'Brian C A
Potent inactivation of representative members of each PKC isozyme subfamily and PKD via S-thiolation by the tumor-promotion/progression antagonist glutathione but not by its precursor cysteine.
Carcinogenesis 2001;22(8):1221-9.
2001: Bedikian A Y; Plager C; Stewart J R; O'Brian C A; Herdman S K; Ross M; Papadopoulos N; Eton O; Ellerhorst J; Smith T
Phase II evaluation of bryostatin-1 in metastatic melanoma.
Melanoma research 2001;11(2):183-8.
2001: Castilleja A; Ward N E; O'Brian C A; Swearingen B; Swan E; Gillogly M A; Murray J L; Kudelka A P; Gershenson D M; Ioannides C G
Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.
Molecular and cellular biochemistry 2001;217(1-2):21-33.
2001: O'Brian C A; Ward N E; Stewart J R; Chu F
Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer--an evolving story.
Cancer metastasis reviews 2001;20(1-2):95-100.
2000: Stewart J R; Christman K L; O'Brian C A
Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation.
Biochemical pharmacology 2000;60(9):1355-9.
2000: Ward N E; Stewart J R; Ioannides C G; O'Brian C A
Oxidant-induced S-glutathiolation inactivates protein kinase C-alpha (PKC-alpha): a potential mechanism of PKC isozyme regulation.
Biochemistry 2000;39(33):10319-29.
1999: Stewart J R; Ward N E; Ioannides C G; O'Brian C A
Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism.
Biochemistry 1999;38(40):13244-51.
1999: Ward N E; Pierce D S; Stewart J R; O'brian C A
A peptide substrate-based affinity label blocks protein kinase C-catalyzed ATP hydrolysis and peptide-substrate phosphorylation.
Archives of biochemistry and biophysics 1999;365(2):248-53.
1999: Ward N E; Fan G; O'Brian C A
Differential non-redox inhibitory effects of glutathione against protein kinase C isozyme family members.
Oncology reports 1999;6(2):307-10.
1998: Bruins R H; Annable C; Ward N E; Gravitt K R; O'Brian C A; Epand R M
Evidence for a regulatory binding site for arginine-rich peptides on protein kinase C.
Archives of biochemistry and biophysics 1998;356(2):258-64.
1998: Ward N E; Pierce D S; Chung S E; Gravitt K R; O'Brian C A
Irreversible inactivation of protein kinase C by glutathione.
The Journal of biological chemistry 1998;273(20):12558-66.
1998: O'Brian C A
Protein kinase C-alpha: a novel target for the therapy of androgen-independent prostate cancer? (Review-hypothesis).
Oncology reports 1998;5(2):305-9.
1997: Beltran P J; Fan D; Fidler I J; O'Brian C A
Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation.
Biochemical pharmacology 1997;53(2):245-7.
1997: Fisk B; Anderson B W; Gravitt K R; O'Brian C A; Kudelka A P; Murray J L; Wharton J T; Ioannides C G
Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes.
Cancer research 1997;57(1):87-93.
1997: Bergman P J; Gravitt K R; Ward N E; Beltran P; Gupta K P; O'Brian C A
Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-glycoprotein-independent mechanism.
Investigational new drugs 1997;15(4):311-8.
1997: Bergman P J; Gravitt K R; O'Brian C A
An N-myristoylated protein kinase C-alpha pseudosubstrate peptide that functions as a multidrug resistance reversal agent in human breast cancer cells is not a P-glycoprotein substrate.
Cancer chemotherapy and pharmacology 1997;40(5):453-6.
1996: Ward N E; Gravitt K R; O'Brian C A
Covalent modification of protein kinase C isozymes by the inactivating peptide substrate analog N-biotinyl-Arg-Arg-Arg-Cys-Leu-Arg-Arg-Leu. Evidence that the biotinylated peptide is an active-site affinity label.
The Journal of biological chemistry 1996;271(39):24193-200.
1996: Gupta K P; Ward N E; Gravitt K R; Bergman P J; O'Brian C A
Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide.
The Journal of biological chemistry 1996;271(4):2102-11.
1995: Fisk B; Savary C; Hudson J M; O'Brian C A; Murray J L; Wharton J T; Ioannides C G
Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(4):197-209.
1995: Ward N E; Gravitt K R; O'Brian C A
Irreversible inactivation of protein kinase C by a peptide-substrate analog.
The Journal of biological chemistry 1995;270(14):8056-60.
1995: Ward N E; Gravitt K R; O'Brian C A
Inhibition of protein kinase C by a synthetic peptide corresponding to cytoplasmic domain residues 828-848 of the human immunodeficiency virus type 1 envelope glycoprotein.
Cancer letters 1995;88(1):37-40.
1995: Killion J J; Beltran P; O'Brian C A; Yoon S S; Fan D; Wilson M R; Fidler I J
The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
Oncology research 1995;7(9):453-9.
1995: O'Brian C A; Ward N E; Gravitt K R; Gupta K P
The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer.
Progress in clinical and biological research 1995;391():117-20.
1994: Gravitt K R; Ward N E; Fan D; Skibber J M; Levin B; O'Brian C A
Evidence that protein kinase C-alpha activation is a critical event in phorbol ester-induced multiple drug resistance in human colon cancer cells.
Biochemical pharmacology 1994;48(2):375-81.
1994: Fisk B; Ioannides C G; Aggarwal S; Wharton J T; O'Brian C A; Restifo N; Glisson B S
Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line.
Lymphokine and cytokine research 1994;13(2):125-31.
1994: Gravitt K R; Ward N E; O'Brian C A
Inhibition of protein kinase C by melittin: antagonism of binding interactions between melittin and the catalytic domain by active-site binding of MgATP.
Biochemical pharmacology 1994;47(2):425-7.
1994: O'Brian C A; Ward N E; Gravitt K R; Fan D
The role of protein kinase C in multidrug resistance.
Cancer treatment and research 1994;73():41-55.
1993: Ward N E; O'Brian C A
Inhibition of protein kinase C by N-myristoylated peptide substrate analogs.
Biochemistry 1993;32(44):11903-9.
1993: Ioannides C G; Fisk B; Fan D; Biddison W E; Wharton J T; O'Brian C A
Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene.
Cellular immunology 1993;151(1):225-34.
1993: Dong Z; O'Brian C A; Fidler I J
Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein-tyrosine kinase activity.
Journal of leukocyte biology 1993;53(1):53-60.
1992: Ward N E; O'Brian C A
The intrinsic ATPase activity of protein kinase C is catalyzed at the active site of the enzyme.
Biochemistry 1992;31(25):5905-11.
1992: Fan D; Fidler I J; Ward N E; Seid C; Earnest L E; Housey G M; O'Brian C A
Stable expression of a cDNA encoding rat brain protein kinase C-beta I confers a multidrug-resistant phenotype on rat fibroblasts.
Anticancer research 1992;12(3):661-7.
1992: Ward N E; O'Brian C A
Kinetic analysis of protein kinase C inhibition by staurosporine: evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates.
Molecular pharmacology 1992;41(2):387-92.
1991: Fan D; O'Brian C A; Ioannides C G; Clyne R K
Granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of cancer.
In vivo (Athens, Greece) 1991;5(6):571-7.
1991: Ward N E; O'Brian C A
Distinct patterns of phorbol ester-induced downregulation of protein kinase C activity in adriamycin-selected multidrug resistant and parental murine fibrosarcoma cells.
Cancer letters 1991;58(3):189-93.
1991: O'Brian C A; Ward N E; Liskamp R M; de Bont D B; Earnest L E; van Boom J H; Fan D
A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to adriamycin.
Investigational new drugs 1991;9(2):169-79.
1991: Dong Z Y; Ward N E; Fan D; Gupta K P; O'Brian C A
In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells.
Molecular pharmacology 1991;39(4):563-9.
1991: O'Brian C A; Fan D; Ward N E; Dong Z; Iwamoto L; Gupta K P; Earnest L E; Fidler I J
Transient enhancement of multidrug resistance by the bile acid deoxycholate in murine fibrosarcoma cells in vitro.
Biochemical pharmacology 1991;41(5):797-806.
1991: O'Brian C A; Ward N E
Stimulation of the ATPase activity of rat brain protein kinase C by phospho acceptor substrates of the enzyme.
Biochemistry 1991;30(9):2549-54.
1991: Ioannides C G; Freedman R S; Patenia R; Bowen J M; Ward N E; O'Brian C A
Immunological effects of tumor vaccines: III. Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells.
In vivo (Athens, Greece) 1991;5(1):1-6.
1990: Staroselsky A N; Fan D; O'Brian C A; Bucana C D; Gupta K P; Fidler I J
Site-dependent differences in response of the UV-2237 murine fibrosarcoma to systemic therapy with adriamycin.
Cancer research 1990;50(24):7775-80.
1990: Ioannides C G; Freedman R S; Liskamp R M; Ward N E; O'Brian C A
Inhibition of IL-2 receptor induction and IL-2 production in the human leukemic cell line Jurkat by a novel peptide inhibitor of protein kinase C.
Cellular immunology 1990;131(1):242-52.
1990: Bucana C D; Giavazzi R; Nayar R; O'Brian C A; Seid C; Earnest L E; Fan D
Retention of vital dyes correlates inversely with the multidrug-resistant phenotype of adriamycin-selected murine fibrosarcoma variants.
Experimental cell research 1990;190(1):69-75.
1990: Fan D; Bucana C D; O'Brian C A; Zwelling L A; Seid C; Fidler I J
Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes.
Cancer research 1990;50(12):3619-26.
1990: O'Brian C A; Ward N E
Characterization of a Ca2(+)- and phospholipid-dependent ATPase reaction catalyzed by rat brain protein kinase C.
Biochemistry 1990;29(18):4278-82.
1990: O'Brian C A; Ward N E; Vogel V G
Inhibition of protein kinase C by the 12-O-tetradecanoylphorbol-13-acetate antagonist glycyrrhetic acid.
Cancer letters 1990;49(1):9-12.
1990: O'Brian C A; Ioannides C G; Ward N E; Liskamp R M
Inhibition of protein kinase C and calmodulin by the geometric isomers cis- and trans-tamoxifen.
Biopolymers 1990;29(1):97-104.
1990: O'Brian C A; Ward N E; Liskamp R M; de Bont D B; van Boom J H
N-myristyl-Lys-Arg-Thr-Leu-Arg: a novel protein kinase C inhibitor.
Biochemical pharmacology 1990;39(1):49-57.
1989: O'Brian C A; Ward N E
ATP-sensitive binding of melittin to the catalytic domain of protein kinase C.
Molecular pharmacology 1989;36(3):355-9.
1989: O'Brian C A; Ward N E
Binding of protein kinase C to N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide through its ATP binding site.
Biochemical pharmacology 1989;38(11):1737-42.
1989: O'Brian C; Vogel V G; Singletary S E; Ward N E
Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue.
Cancer research 1989;49(12):3215-7.
1989: Ioannides C G; Platsoucas C D; O'Brian C A; Patenia R; Bowen J M; Wharton J T; Freedman R S
Viral oncolysates in cancer treatment: immunological mechanisms of action (review).
Anticancer research 1989;9(3):535-44.
1989: O'Brian C A; Fan D; Ward N E; Seid C; Fidler I J
Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells.
FEBS letters 1989;246(1-2):78-82.
1988: O'Brian C A; Ward N E; Anderson B W
Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme.
Journal of the National Cancer Institute 1988;80(20):1628-33.
1988: Ward N E; O'Brian C A
The bile acid analog fusidic acid can replace phosphatidylserine in the activation of protein kinase C by 12-O-tetradecanoylphorbol-13-acetate in vitro.
Carcinogenesis 1988;9(8):1451-4.
1988: O'Brian C A; Housey G M; Weinstein I B
Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue.
Cancer research 1988;48(13):3626-9.
1988: Housey G M; Johnson M D; Hsiao W L; O'Brian C A; Murphy J P; Kirschmeier P; Weinstein I B
Overproduction of protein kinase C causes disordered growth control in rat fibroblasts.
Cell 1988;52(3):343-54.
1988: Housey G M; Johnson M D; Hsiao W L; O'Brian C A; Weinstein I B
Structural and functional studies of protein kinase C.
Advances in experimental medicine and biology 1988;234():127-40.
1987: O'Brian C A; Housey G M; Weinstein I B
Binding of protein kinase C to napthalenesulfonamide- and phenothiazine-agarose columns: evidence for direct interactions between protein kinase C and cationic amphiphilic inhibitors of the enzyme.
Biochemical pharmacology 1987;36(23):4179-81.
1987: Guillem J G; O'Brian C A; Fitzer C J; Johnson M D; Forde K A; LoGerfo P; Weinstein I B
Studies on protein kinase C and colon carcinogenesis.
Archives of surgery (Chicago, Ill. : 1960) 1987;122(12):1475-8.
1987: Johnson M D; Housey G M; O'Brian C A; Kirschmeier P T; Weinstein I B
Role of protein kinase C in regulation of gene expression and relevance to tumor promotion.
Environmental health perspectives 1987;76():89-95.
1987: Guillem J G; O'Brian C A; Fitzer C J; Forde K A; LoGerfo P; Treat M; Weinstein I B
Altered levels of protein kinase C and Ca2+-dependent protein kinases in human colon carcinomas.
Cancer research 1987;47(8):2036-9.
1987: Fitzer C J; O'Brian C A; Guillem J G; Weinstein I B
The regulation of protein kinase C by chenodeoxycholate, deoxycholate and several structurally related bile acids.
Carcinogenesis 1987;8(2):217-20.
1986: O'Brian C A; Liskamp R M; Solomon D H; Weinstein I B
Triphenylethylenes: a new class of protein kinase C inhibitors.
Journal of the National Cancer Institute 1986;76(6):1243-6.
1986: Weinstein I B; O'Brian C A; Housey G M; Johnson M D; Kirschmeier P; Hsiao W
Studies on the mechanism of action of protein kinase C and the isolation of molecular clones encoding the enzyme.
Symposium on Fundamental Cancer Research 1986;39():173-83.
1985: O'Brian C A; Liskamp R M; Solomon D H; Weinstein I B
Inhibition of protein kinase C by tamoxifen.
Cancer research 1985;45(6):2462-5.

Sign-in to see more